Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
+0.28 (+0.36%)
4:00:00 PM EDT: $78.27 +0.14 (+0.18%)
Products, Strategic Combinations

Ngm Amends Collaboration With Merck To Focus Primarily On Advancing Novel Medicines For Retinal And Cardiovascular And Metabolic Diseases

Published: 07/01/2021 11:14 GMT
Merck & Co Inc (MRK) - Ngm Amends Collaboration With Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (cvm) Diseases.
Ngm Biopharmaceuticals Inc - to Extend Their Ongoing Collaboration Through March 2024 But With a Narrower Scope.
Ngm Biopharmaceuticals - Under Terms of Amended Collaboration, Merck Will Provide About $120 Million in Research and Development Funding to Ngm Through March 2024.